Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

NCT01925950 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped due to patient enrollment challenges.

Conditions

Chronic Gastrointestinal Graft vs Host Disease

Interventions

DRUG: orBec
DRUG: Placebo

Sponsor

Soligenix